Radioactive iodine-125 (I-125) is the most widely used radioactive sealed source for
interstitial permanent brachytherapy (BT). BT has the exceptional ability to deliver extremely …

Abstract Background and Purpose High dose-rate (HDR) brachytherapy as a monotherapy
is an accepted treatment for localized prostate cancer, but the optimal dose and fractionation …

Advances in imaging have changed prostate radiotherapy through improved biochemical
control from focal boost and improved detection of recurrence. These advances are …

Background and purpose The optimal dose for prostate stereotactic body radiotherapy
(SBRT) is still unknown. This study evaluated the dose–response relationships for prostate …

Purpose Low-dose-rate (LDR) brachytherapy and stereotactic body radiation therapy
(SBRT) have both shown acceptable outcomes in the treatment of low-and intermediate-risk …

Abstract Background and purpose The Phoenix definition for biochemical failure (BCF) after
radiotherapy uses nadir PSA (nPSA)+ 2 ng/mL to classify a BCF and was derived from …

Simple Summary Stereotactic radiation therapy consists of delivering ablative ultra-high
doses of radiation to a precise target in a very limited number of fractions. Because of its …

Immune regulation plays a vital role in ischemia–reperfusion injury (IRI). Butyric acid (BA)
has immunomodulatory effects in many diseases, but its immunomodulatory effects during …

Purpose Dose-escalated radiation therapy is associated with better biochemical control at
the expense of toxicity. Stereotactic body radiation therapy (SBRT) with dose escalation to …

Simple Summary Radiation therapy is a standard of care treatment option for men with
localized prostate cancer. Over the years, various radiation delivery modalities have …